Elizabeth Park Capital Advisors LTD Has Upped Qcr Holdings (QCRH) Position By $328,000; Keryx Biopharmaceuticals (KERX) Has 0.76 Sentiment

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Logo

Elizabeth Park Capital Advisors Ltd increased Qcr Holdings Inc (QCRH) stake by 3.48% reported in 2018Q3 SEC filing. Elizabeth Park Capital Advisors Ltd acquired 8,200 shares as Qcr Holdings Inc (QCRH)’s stock declined 21.58%. The Elizabeth Park Capital Advisors Ltd holds 243,691 shares with $9.96M value, up from 235,491 last quarter. Qcr Holdings Inc now has $545.74M valuation. The stock increased 0.20% or $0.07 during the last trading session, reaching $34.72. About 14,299 shares traded. QCR Holdings, Inc. (NASDAQ:QCRH) has declined 24.55% since February 13, 2018 and is downtrending. It has underperformed by 24.55% the S&P500. Some Historical QCRH News: 11/05/2018 – Maltese Capital Management LLC Exits Position in QCR; 20/03/2018 – QCR Holdings: Bates Transaction Expected to Close Late in 2Q or Early 3Q of 2018; 22/03/2018 – QCR Closes Below 200-Day Moving Average: Technicals; 18/04/2018 – QCR HOLDINGS INC – MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES; 24/05/2018 – QCR Holdings, Inc. Welcomes New Director Mary Kay Bates and Announces a Cash Dividend of $0.06 per Share; 18/04/2018 – QCR HOLDINGS INC – TRANSACTION IS VALUED AT APPROXIMATELY $86.7 MLN; 18/04/2018 – QCR Holdings 1Q Adj EPS 70c; 20/03/2018 – QCR HOLDINGS INC – IN FIRST FULL YEAR AFTER MERGER, 2019, TRANSACTION IS EXPECTED TO BE 0.3% ACCRETIVE TO EPS EXCLUDING IMPACT OF FUTURE CONSIDERATION; 20/03/2018 QCR Holdings, Inc. Announces Plans To Acquire The Bates Companies; 24/05/2018 – QCR Holdings, Inc. Welcomes New Director Mary Kay Bates and Announces a Cash Div of $0.06 Per Shr

Keryx Biopharmaceuticals Inc (KERX) investors sentiment decreased to 0.76 in Q3 2018. It’s down -0.98, from 1.74 in 2018Q2. The ratio dived, as 38 hedge funds increased and started new equity positions, while 50 decreased and sold their stakes in Keryx Biopharmaceuticals Inc. The hedge funds in our database reported: 69.50 million shares, down from 71.09 million shares in 2018Q2. Also, the number of hedge funds holding Keryx Biopharmaceuticals Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 17 Reduced: 33 Increased: 26 New Position: 12.

Investors sentiment decreased to 1.19 in 2018 Q3. Its down 0.18, from 1.37 in 2018Q2. It fall, as 14 investors sold QCRH shares while 28 reduced holdings. 12 funds opened positions while 38 raised stakes. 9.05 million shares or 3.55% more from 8.73 million shares in 2018Q2 were reported. Us Natl Bank De holds 3,868 shares or 0% of its portfolio. Schwab Charles Invest Incorporated holds 0% in QCR Holdings, Inc. (NASDAQ:QCRH) or 72,203 shares. Metropolitan Life Insurance holds 0% in QCR Holdings, Inc. (NASDAQ:QCRH) or 908 shares. State Bank Of Montreal Can invested in 0% or 90 shares. Prudential has invested 0.01% in QCR Holdings, Inc. (NASDAQ:QCRH). Blackrock reported 917,087 shares. Manufacturers Life Ins The owns 229,072 shares or 0.01% of their US portfolio. Paloma Ptnrs Mgmt has invested 0.01% in QCR Holdings, Inc. (NASDAQ:QCRH). Rothschild & Co Asset Mngmt Us Incorporated stated it has 0.02% in QCR Holdings, Inc. (NASDAQ:QCRH). Banc Funds Ltd Liability Com reported 309,561 shares. Comm Financial Bank reported 55,835 shares. Great West Life Assurance Co Can, Manitoba – Canada-based fund reported 1,412 shares. Bkd Wealth Advsr Lc invested in 0.07% or 18,884 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 1,608 shares for 0% of their portfolio. Credit Suisse Ag holds 11,669 shares.

More notable recent QCR Holdings, Inc. (NASDAQ:QCRH) news were published by: Nasdaq.com which released: “QCR Holdings (QCRH) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release – Nasdaq” on January 17, 2019, also Nasdaq.com with their article: “QCRH vs. FFBC: Which Stock Is the Better Value Option? – Nasdaq” published on January 17, 2019, Nasdaq.com published: “QCR Holdings, Inc. Announces Record Net Income for the Fourth Quarter and Full Year 2018 – Nasdaq” on January 24, 2019. More interesting news about QCR Holdings, Inc. (NASDAQ:QCRH) were released by: Seekingalpha.com and their article: “QCR Holdings, Inc. (QCRH) CEO Doug Hultquist on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on January 25, 2019 as well as Fool.com‘s news article titled: “QCR Holdings Inc (QCRH) Q4 2018 Earnings Conference Call Transcript – Motley Fool” with publication date: January 25, 2019.

Since September 19, 2018, it had 5 insider buys, and 1 sale for $748,433 activity. $670,294 worth of QCR Holdings, Inc. (NASDAQ:QCRH) shares were bought by Peterson Michael Lawrence. 2,564 shares were bought by GIPPLE TODD A, worth $86,663 on Tuesday, December 11. The insider Grabin Elizabeth A bought 410 shares worth $13,858. Shares for $35,432 were sold by BUDD THOMAS D. Ziegler Marie Z. also bought $6,490 worth of QCR Holdings, Inc. (NASDAQ:QCRH) shares.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $404.46 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

More notable recent Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) news were published by: Nasdaq.com which released: “Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall – Nasdaq” on June 29, 2018, also Nasdaq.com with their article: “Keryx (KERX) Looks Good: Stock Adds 7.2% in Session – Nasdaq” published on November 26, 2018, Seekingalpha.com published: “Akebia Therapeutics and Keryx Biopharmaceuticals complete merger – Seeking Alpha” on December 13, 2018. More interesting news about Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) were released by: Nasdaq.com and their article: “Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat – Nasdaq” published on May 11, 2018 as well as Globenewswire.com‘s news article titled: “Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics – GlobeNewswire” with publication date: December 11, 2018.

The stock decreased 2.04% or $0.07 during the last trading session, reaching $3.36. About 2.60M shares traded or 97.65% up from the average. Keryx Biopharmaceuticals, Inc. (KERX) has declined 27.37% since February 13, 2018 and is downtrending. It has underperformed by 27.37% the S&P500. Some Historical KERX News: 04/04/2018 – Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology; 11/04/2018 – Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation; 04/04/2018 – KERYX BIOPHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM THE PHASE 3 TRIAL OF AURYXIA® (FERRIC CITRATE) FOR IRON DEFICIENCY ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE, NOT ON DIALYSIS, IN THE…; 08/05/2018 – The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes it; 13/03/2018 – Keryx Closes Below 50-Day Moving Average: Technicals; 19/04/2018 – Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress; 04/04/2018 – KERYX: ANALYSIS OF AURYXIA DATA SUPPORT KDIGO GUIDELINES; 24/05/2018 – Keryx Presenting at ERA-EDTA Annual Congress 2018 Tomorrow; 25/05/2018 – Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chroni; 07/05/2018 – Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2018 Financial Results on Thursday, May 10, 2018

QCR Holdings, Inc. (NASDAQ:QCRH) Institutional Positions Chart